Erythropoietin (EPO)
Also known as: EPO, Erythropoietin, Epoetin, rHuEPO
EPO | Red Blood Cell Stimulating Hormone
Overview
Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow cells promotes survival and maturation of red blood cell precursors, increasing oxygen-carrying capacity. Due to performance-enhancing effects, it is banned in competitive sports.
Key benefits
- Stimulates red blood cell production
- Increases oxygen-carrying capacity
- FDA-approved for anemia treatment
- Improves endurance capacity
- Supports patients with chronic kidney disease
- Helps chemotherapy-induced anemia
- Well-characterized mechanism of action
- Extensively studied safety profile
Mechanism of action
EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of erythroid cells, and increases hemoglobin production. Under hypoxic stress, endogenous EPO production can increase up to 1000-fold, demonstrating the body's powerful oxygen-sensing regulatory system.
Molecular data
- Type
- Glycoprotein hormone
- Half-life
- 4-12 hours (IV), ~25 hours (SubQ)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Medical Indications (FDA-Approved)
CKD-Related Anemia
Most effectivePrimary FDA-approved indication for anemia secondary to chronic kidney disease.
Chemotherapy-Induced Anemia
Most effectiveFDA-approved for treating anemia in cancer patients receiving chemotherapy.
Surgical Blood Loss
EffectiveUsed to reduce need for blood transfusions in certain surgical settings.
Performance (Banned in Sports)
Endurance Enhancement
Most effectiveIncreases oxygen delivery to muscles, improving endurance capacity. Banned by WADA.
Altitude Acclimatization
EffectiveMay accelerate adaptation to high altitude by increasing red blood cell mass.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
EPO is administered via subcutaneous or intravenous injection. Medical use requires prescription and monitoring. Dosing is individualized based on hemoglobin levels, with targets typically kept below 11-12 g/dL to minimize cardiovascular risks.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| CKD Anemia (medical) | 50-100 IU/kg | 3x weekly | SubQ or IV |
| Chemotherapy Anemia (medical) | 150-300 IU/kg | 3x weekly | SubQ |
| Maintenance (medical) | Individualized | 1-3x weekly | SubQ |
Preparation
You will need
- Pre-filled syringes (most common)
- Or lyophilized powder with diluent
- Alcohol swabs
- Cold storage
Steps
- Most EPO comes in pre-filled syringes
- Allow to reach room temperature before injection
- Inject subcutaneously or intravenously as directed
- Do not shake vials or syringes
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Iron supplementation
SynergisticIron is essential for hemoglobin production; often co-administered with EPO therapy.
TB-500
CompatibleDifferent mechanisms; no known interactions.
BPC-157
CompatibleDifferent mechanisms; no known interactions.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Days 1-3
Bone marrow stimulation begins
- Week 1-2
Reticulocyte count increases
- Week 2-4
Hemoglobin begins rising
- Week 4-12
Target hemoglobin achieved with proper dosing
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Injection site reactions
- Headache
- Hypertension
- Joint pain
- Flu-like symptoms
Rare side effects
- Pure red cell aplasia (very rare)
- Thromboembolic events
- Stroke
- Myocardial infarction
- Tumor progression (theoretical)
Stop signs — stop and seek advice
- Severe headache or vision changes
- Chest pain or shortness of breath
- Signs of blood clots (leg swelling, pain)
- Sudden loss of response to EPO
Contraindications
- Uncontrolled hypertension
- Pure red cell aplasia history
- Hemoglobin >12 g/dL (increased cardiovascular risk)
- Active malignancy (relative contraindication)
Monitoring
- Regular hemoglobin monitoring essential
- Blood pressure monitoring
- Iron status assessment
- Keep hemoglobin below 11-12 g/dL to reduce risks
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- Clear, colorless solution
- Pharmaceutical grade product
- Proper cold chain maintained
- Intact packaging and seals
Warning signs
- Research-grade products lack quality assurance
- Temperature excursions may affect potency
Stop signs — don't use
- Cloudy or discolored solution
- Particulates visible
- Exposed to room temperature
References
Primary literature and clinical-trial data informing this entry.
Erythropoietin regulation of red blood cell production
PMC/NCBI · 2020
Comprehensive review of EPO's oxygen-sensing mechanism and regulation of RBC production.
Erythropoietin Stimulating Agents
StatPearls (NCBI Bookshelf) · 2024
FDA-approved indications include CKD anemia and chemotherapy-induced anemia. Risks increase when hemoglobin exceeds 11-12 g/dL.
Erythropoiesis-stimulating agents and other methods to enhance oxygen transport
PMC · 2008
rHuEPO increases O2 supply to muscles and boosts performance in endurance sports.
The mechanism of erythropoietin action
PubMed · 1992
EPO promotes survival of erythroid progenitors by protecting from apoptosis.
Last updated . How this page was sourced is described in the methodology.